• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $CGON

    CG Oncology Inc.

    Subscribe to $CGON
    $CGON
    00

    IPO Year: 2024

    Exchange: NASDAQ

    Recent Analyst Ratings for CG Oncology Inc.

    DatePrice TargetRatingAnalyst
    5/2/2025$41.00Overweight
    Analyst
    4/16/2025$23.00Sector Perform
    Scotiabank
    1/7/2025Buy
    TD Cowen
    10/24/2024$60.00Buy
    UBS
    9/23/2024$66.00Outperform
    RBC Capital Mkts
    8/28/2024$65.00Buy
    ROTH MKM
    6/28/2024$65.00Buy
    BofA Securities
    2/20/2024$75.00Overweight
    Cantor Fitzgerald
    2/20/2024$42.00Neutral
    Goldman
    2/20/2024$55.00Overweight
    Morgan Stanley
    See more ratings

    CG Oncology Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Decheng Capital Global Life Sciences Fund Iv, L.P. bought $7,600,000 worth of shares (400,000 units at $19.00) (SEC Form 4) (Amendment)

      4/A - CG Oncology, Inc. (0001991792) (Issuer)

      4/9/24 7:08:23 PM ET
      $CGON

    CG Oncology Inc. SEC Filings

    See more
    • CG Oncology Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - CG Oncology, Inc. (0001991792) (Filer)

      4/28/25 7:30:08 AM ET
      $CGON
    • SEC Form DEFA14A filed by CG Oncology Inc.

      DEFA14A - CG Oncology, Inc. (0001991792) (Filer)

      4/25/25 8:09:30 AM ET
      $CGON
    • SEC Form DEF 14A filed by CG Oncology Inc.

      DEF 14A - CG Oncology, Inc. (0001991792) (Filer)

      4/25/25 8:05:53 AM ET
      $CGON
    • SEC Form S-3ASR filed by CG Oncology Inc.

      S-3ASR - CG Oncology, Inc. (0001991792) (Filer)

      3/28/25 4:57:46 PM ET
      $CGON
    • SEC Form 10-K filed by CG Oncology Inc.

      10-K - CG Oncology, Inc. (0001991792) (Filer)

      3/28/25 8:59:13 AM ET
      $CGON
    • CG Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - CG Oncology, Inc. (0001991792) (Filer)

      3/28/25 7:15:08 AM ET
      $CGON
    • CG Oncology Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - CG Oncology, Inc. (0001991792) (Filer)

      3/24/25 8:30:09 AM ET
      $CGON
    • SEC Form 144 filed by CG Oncology Inc.

      144 - CG Oncology, Inc. (0001991792) (Subject)

      3/17/25 4:38:08 PM ET
      $CGON
    • Amendment: SEC Form SCHEDULE 13G/A filed by CG Oncology Inc.

      SCHEDULE 13G/A - CG Oncology, Inc. (0001991792) (Subject)

      2/14/25 5:40:02 PM ET
      $CGON
    • Amendment: SEC Form SCHEDULE 13G/A filed by CG Oncology Inc.

      SCHEDULE 13G/A - CG Oncology, Inc. (0001991792) (Subject)

      1/28/25 5:08:33 PM ET
      $CGON

    CG Oncology Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Post Leonard E exercised 1,000 shares at a strike of $0.60 and sold $30,760 worth of shares (1,000 units at $30.76) (SEC Form 4)

      4 - CG Oncology, Inc. (0001991792) (Issuer)

      4/29/25 4:15:03 PM ET
      $CGON
    • SEC Form 4 filed by Chief Executive Officer Kuan Arthur

      4 - CG Oncology, Inc. (0001991792) (Issuer)

      4/16/25 4:15:18 PM ET
      $CGON
    • SEC Form 4 filed by President and COO Bellete Ambaw

      4 - CG Oncology, Inc. (0001991792) (Issuer)

      4/16/25 4:15:17 PM ET
      $CGON
    • SEC Form 4 filed by CFO Roche Corleen M.

      4 - CG Oncology, Inc. (0001991792) (Issuer)

      4/16/25 4:15:09 PM ET
      $CGON
    • SEC Form 4 filed by Officer Patterson Joshua F.

      4 - CG Oncology, Inc. (0001991792) (Issuer)

      4/16/25 4:15:12 PM ET
      $CGON
    • SEC Form 4 filed by Chief Medical Officer Kasturi Vijay

      4 - CG Oncology, Inc. (0001991792) (Issuer)

      4/16/25 4:15:15 PM ET
      $CGON
    • Director Post Leonard E exercised 1,000 shares at a strike of $0.60 and sold $28,000 worth of shares (1,000 units at $28.00) (SEC Form 4)

      4 - CG Oncology, Inc. (0001991792) (Issuer)

      3/18/25 4:30:26 PM ET
      $CGON
    • Director Post Leonard E exercised 1,000 shares at a strike of $0.60 and sold $28,610 worth of shares (1,000 units at $28.61) (SEC Form 4)

      4 - CG Oncology, Inc. (0001991792) (Issuer)

      2/19/25 4:15:05 PM ET
      $CGON
    • Director Post Leonard E exercised 1,000 shares at a strike of $0.60 and sold $29,660 worth of shares (1,000 units at $29.66) (SEC Form 4)

      4 - CG Oncology, Inc. (0001991792) (Issuer)

      1/14/25 4:16:52 PM ET
      $CGON
    • Director Song Hong Fang sold $19,600,000 worth of shares (700,000 units at $28.00) (SEC Form 4)

      4 - CG Oncology, Inc. (0001991792) (Issuer)

      12/17/24 6:03:16 PM ET
      $CGON

    CG Oncology Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Analyst initiated coverage on CG Oncology with a new price target

      Analyst initiated coverage of CG Oncology with a rating of Overweight and set a new price target of $41.00

      5/2/25 8:14:21 AM ET
      $CGON
    • Scotiabank initiated coverage on CG Oncology with a new price target

      Scotiabank initiated coverage of CG Oncology with a rating of Sector Perform and set a new price target of $23.00

      4/16/25 8:09:10 AM ET
      $CGON
    • TD Cowen initiated coverage on CG Oncology

      TD Cowen initiated coverage of CG Oncology with a rating of Buy

      1/7/25 7:46:13 AM ET
      $CGON
    • UBS initiated coverage on CG Oncology with a new price target

      UBS initiated coverage of CG Oncology with a rating of Buy and set a new price target of $60.00

      10/24/24 6:18:20 AM ET
      $CGON
    • RBC Capital Mkts initiated coverage on CG Oncology with a new price target

      RBC Capital Mkts initiated coverage of CG Oncology with a rating of Outperform and set a new price target of $66.00

      9/23/24 7:28:55 AM ET
      $CGON
    • ROTH MKM initiated coverage on CG Oncology with a new price target

      ROTH MKM initiated coverage of CG Oncology with a rating of Buy and set a new price target of $65.00

      8/28/24 7:38:28 AM ET
      $CGON
    • BofA Securities initiated coverage on CG Oncology with a new price target

      BofA Securities initiated coverage of CG Oncology with a rating of Buy and set a new price target of $65.00

      6/28/24 7:35:12 AM ET
      $CGON
    • Cantor Fitzgerald initiated coverage on CG Oncology with a new price target

      Cantor Fitzgerald initiated coverage of CG Oncology with a rating of Overweight and set a new price target of $75.00

      2/20/24 7:25:43 AM ET
      $CGON
    • Goldman initiated coverage on CG Oncology with a new price target

      Goldman initiated coverage of CG Oncology with a rating of Neutral and set a new price target of $42.00

      2/20/24 6:50:19 AM ET
      $CGON
    • Morgan Stanley initiated coverage on CG Oncology with a new price target

      Morgan Stanley initiated coverage of CG Oncology with a rating of Overweight and set a new price target of $55.00

      2/20/24 6:49:58 AM ET
      $CGON

    CG Oncology Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more

    CG Oncology Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SUO-CTC and CG Oncology Announce the 2025 Award Recipients for the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

      - Award recipients Honored at the American Urological Association's 2025 Annual Meeting - - Fellowship designed to support the development of outstanding clinical cancer research investigators to improve the understanding and treatment of NMIBC - SCHAUMBURG, Ill. and IRVINE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), a national alliance of leading academic and community based uro-oncologists, and CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced t

      5/1/25 8:00:00 AM ET
      $CGON
    • CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting

      - Robust 24-month complete response rate of 42.3% by K-M for cretostimogene monotherapy in BOND-003 Cohort C – - 58.3% of patients showed durable complete responses by K-M at 24 months – - 97.3% of all treated patients remained free from progression to MIBC at 24 months– - 91.6% of responders remained cystectomy-free at 24 months – - No Grade 3 or greater treatment-related adverse events or deaths reported – - Strong initial Cohort P data reported 90.5% high-grade recurrence-free survival at 3 and 9 months by K-M – - Company will host a conference call and webcast at 8 a.m. EDT on Monday, April 28, 2025 - IRVINE, Calif., April 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:C

      4/26/25 4:10:03 PM ET
      $CGON
    • CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025

      IRVINE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced it will host a conference call and live webcast at 8:00 am ET on April 28, 2025, to discuss results from the Phase 3 BOND-003 trial of cretostimogene monotherapy in high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) to be presented on April 26, 2025, at a Plenary Session at the American Urological Association (AUA) Annual Meeting in Las Vegas, Nevada. Individuals can access the webcast via the link on

      4/24/25 8:00:00 AM ET
      $CGON
    • CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates

      - Durability Results from BOND-003 data will be presented as a late breaker as part of AUA's Practice-changing, Paradigm-shifting Clinical Trials in Urology - - Additional updates from across CG Oncology's clinical trial program, including translational data, planned - IRVINE, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced BOND-003 study of cretostimogene monotherapy in high-risk BCG-unresponsive non-muscle invasive bladder cancer has been selected as a late breaker as part

      3/31/25 8:00:00 AM ET
      $CGON
    • CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates

      - Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated CORE-008 Clinical Trial of Cretostimogene Monotherapy in High-Risk BCG-Naïve (Cohort A) and BCG-Exposed (Cohort B) NMIBC - - Late-Breaking Clinical and First Translational Data from BOND-003 Cohort C Presented at the 40th Annual European Association of Urology Congress - - Completed Oversubscribed $238 Million Follow-on Public Equity Offering that Extends Expected Runway into the First Half of 2028 - IRVINE, Calif., March 28, 2025 (GLOBE NEWS

      3/28/25 7:00:00 AM ET
      $CGON
    • Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy

      – Latest BOND-003 data show 75.5% of patients achieved a complete response at any time –– Median duration of response exceeds 28 months and is ongoing –– No close contact precautions needed post cretostimogene treatment – IRVINE, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that 83 out of 110 patients (75.5%) achieved a complete response (CR) at any time in a Phase 3 study of cretostimogene monotherapy for high-risk BCG-unresponsive non-muscle invasive bladder cancer wit

      3/24/25 8:00:00 AM ET
      $CGON
    • CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates

      IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that a late-breaking abstract on BOND-003 Cohort C, as well as three posters highlighting cretostimogene grenadenorepvec, will be presented at the 40th Annual European Association of Urology (EAU) Congress taking place in Madrid, Spain, from March 21-24, 2025. The Annual EAU Congress is Europe's biggest urological event, where thousands of healthcare professionals from around the world gather to present research and learn

      3/12/25 8:00:00 AM ET
      $CGON
    • CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference

      IRVINE, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer, today announced that Arthur Kuan, Chairman & Chief Executive Officer, is scheduled to present at the TD Cowen 45th Annual Health Care Conference in Boston, MA on Wednesday, March 5, 2025, at 11:10 am ET. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.cgoncology.com. The webcast replay will be available after the conclusion of the live

      2/26/25 8:00:00 AM ET
      $CGON
    • CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

      IRVINE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer, today announced the closing of its public offering of 9,200,000 shares of its common stock, 8,500,000 of which were offered by CG Oncology, which includes the exercise in full by the underwriters of their option to purchase 1,200,000 additional shares, and 700,000 of which were offered by an existing stockholder of CG Oncology, each at a public offering price of $28.00 per share. The gross proceeds to CG Oncology from the offeri

      12/16/24 4:05:00 PM ET
      $CGON
    • CG Oncology Announces Pricing of Public Offering

      IRVINE, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer, today announced the pricing of its public offering of 8,000,000 shares of its common stock, 7,300,000 of which are being offered by CG Oncology and 700,000 of which are being offered by an existing stockholder of CG Oncology, each at a public offering price of $28.00 per share. The gross proceeds to CG Oncology from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to

      12/12/24 8:19:18 PM ET
      $CGON
    • Amendment: SEC Form SC 13G/A filed by CG Oncology Inc.

      SC 13G/A - CG Oncology, Inc. (0001991792) (Subject)

      11/12/24 2:30:47 PM ET
      $CGON
    • Amendment: SEC Form SC 13G/A filed by CG Oncology Inc.

      SC 13G/A - CG Oncology, Inc. (0001991792) (Subject)

      11/4/24 10:22:51 AM ET
      $CGON
    • SEC Form SC 13G filed by CG Oncology Inc.

      SC 13G - CG Oncology, Inc. (0001991792) (Subject)

      7/22/24 4:35:57 PM ET
      $CGON
    • SEC Form SC 13G/A filed by CG Oncology Inc. (Amendment)

      SC 13G/A - CG Oncology, Inc. (0001991792) (Subject)

      4/9/24 7:12:20 PM ET
      $CGON
    • SEC Form SC 13G filed by CG Oncology Inc.

      SC 13G - CG Oncology, Inc. (0001991792) (Subject)

      3/14/24 7:25:25 PM ET
      $CGON

    CG Oncology Inc. Financials

    Live finance-specific insights

    See more
    • CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting

      - Robust 24-month complete response rate of 42.3% by K-M for cretostimogene monotherapy in BOND-003 Cohort C – - 58.3% of patients showed durable complete responses by K-M at 24 months – - 97.3% of all treated patients remained free from progression to MIBC at 24 months– - 91.6% of responders remained cystectomy-free at 24 months – - No Grade 3 or greater treatment-related adverse events or deaths reported – - Strong initial Cohort P data reported 90.5% high-grade recurrence-free survival at 3 and 9 months by K-M – - Company will host a conference call and webcast at 8 a.m. EDT on Monday, April 28, 2025 - IRVINE, Calif., April 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:C

      4/26/25 4:10:03 PM ET
      $CGON
    • CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025

      IRVINE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced it will host a conference call and live webcast at 8:00 am ET on April 28, 2025, to discuss results from the Phase 3 BOND-003 trial of cretostimogene monotherapy in high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) to be presented on April 26, 2025, at a Plenary Session at the American Urological Association (AUA) Annual Meeting in Las Vegas, Nevada. Individuals can access the webcast via the link on

      4/24/25 8:00:00 AM ET
      $CGON
    • CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates

      - Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated CORE-008 Clinical Trial of Cretostimogene Monotherapy in High-Risk BCG-Naïve (Cohort A) and BCG-Exposed (Cohort B) NMIBC - - Late-Breaking Clinical and First Translational Data from BOND-003 Cohort C Presented at the 40th Annual European Association of Urology Congress - - Completed Oversubscribed $238 Million Follow-on Public Equity Offering that Extends Expected Runway into the First Half of 2028 - IRVINE, Calif., March 28, 2025 (GLOBE NEWS

      3/28/25 7:00:00 AM ET
      $CGON
    • Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

      – 74.5% of patients achieved a complete response at any time – – Median duration of response is greater than 27 months and not reached – – Latest data update continued to show favorable safety and tolerability results – – Company hosting virtual investor event with lead investigator at 8 am EST today – IRVINE, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced topline data from the Phase 3 BOND-003 trial in patients with high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) unr

      12/5/24 7:00:00 AM ET
      $CGON
    • CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024

      IRVINE, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced it will host a conference call and live webcast at 7 am CST on December 5, 2024, to discuss results from the Phase 3 BOND-003 trial of cretostimogene monotherapy in high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). In addition to company executives, this call will feature Mark Tyson, II, M.D., M.P.H., urologic oncologist at Mayo Clinic, and lead investigator in the BOND-003 study. Dr. Tyson is presenti

      12/2/24 8:00:00 AM ET
      $CGON
    • Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

      - Phase 3 BOND-003 study results showed sustained, durable complete responses over 12 months with novel investigational oncolytic immunotherapy - - Company will hold an investor conference call today at 4:30pm EDT - IRVINE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. today announced that data from the Phase 3 BOND-003 study evaluating the efficacy and safety of cretostimogene monotherapy in patients with high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette Guerin (BCG), showed that 75.2% of patients (79 out of 105 [95% confidence interval (CI), 65-83]) achieved a complete response (CR) at any time, as of the cutoff date of April 1, 202

      5/3/24 11:23:00 AM ET
      $CGON